BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies-Reference-Cited by-同舟云学术

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

Published:2014-01-23 Issue:8 Volume:28 Page:1657-1665
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Bogenberger J M,Kornblau S M,Pierceall W E,Lena R,Chow D,Shi C-X,Mantei J,Ahmann G,Gonzales I M,Choudhary A,Valdez R,Camoriano J,Fauble V,Tiedemann R E,Qiu Y H,Coombes K R,Cardone M,Braggio E,Yin H,Azorsa D O,Mesa R A,Stewart A K,Tibes R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201444.pdf

Reference47 articles.

1. Mesa RA, Tibes R . MPN blast phase: clinical challenge and assessing response. Leuk Res 2012; 36: 1496–1497.

2. Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res 2012; 36: 1147–1151.

3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.

4. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29: 1987–1996.

5. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010; 116: 3735–3742.

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful Treatment With Venetoclax Plus Azacytidine Combined With Radiation Therapy and Donor Lymphocyte Infusion in a Patient With Extramedullary Relapse of Acute Myeloid Leukemia After Stem Cell Transplantation;Cureus;2024-02-05

2. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?;Journal of Clinical Medicine;2024-01-18

3. Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance;International Journal of Molecular Sciences;2023-12-29

4. Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression;Apoptosis;2023-12-08

5. Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies;International Journal of Molecular Sciences;2023-11-24